Skip to main content

FDA Approvals

FDA Approved Rivfloza for Treatment of Primary Hyperoxaluria Type 1 in Children and Adults

Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation

Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma

Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer

IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC

Jerm Day-Storms, PhD, MWC

FDA Pipeline, October-December 2023

FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA

Jerm Day-Storms, PhD, MWC

FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023

FDA Approvals, Bispecific Antibodies

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

Page 4 of 53
Results 31 - 40 of 522